{"id": "article-27139_0", "title": "Phosphodiesterase Inhibitors -- Continuing Education Activity", "content": "Phosphodiesterase inhibitors are class medications used in the management and treatment of chronic obstructive pulmonary disease(COPD), erectile dysfunction(ED), pulmonary arterial hypertension(PAH), benign prostatic hyperplasia(BPH), acute decompensated heart failure, psoriasis, psoriatic arthritis(PA), atopic dermatitis(AD), and neonatal apnea. In the class of medications that prevent cAMP and/or cGMP degradation, it exhibits smooth muscle relaxation, vasodilatory, and bronchodilatory effects. This activity outline and describes the indications, action, and contraindications for phosphodiesterase inhibitors as a valuable agent in the management of chronic obstructive pulmonary disease(COPD), erectile dysfunction(ED), pulmonary arterial hypertension(PAH), acute decompensated heart failure, psoriasis, psoriatic arthritis(PA), and other disorders when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, monitoring, relevant interactions) pertinent for members of the interprofessional team in the management and care of patients with chronic obstructive pulmonary disease(COPD), erectile dysfunction(ED), pulmonary arterial hypertension(PAH), and related conditions.", "contents": "Phosphodiesterase Inhibitors -- Continuing Education Activity. Phosphodiesterase inhibitors are class medications used in the management and treatment of chronic obstructive pulmonary disease(COPD), erectile dysfunction(ED), pulmonary arterial hypertension(PAH), benign prostatic hyperplasia(BPH), acute decompensated heart failure, psoriasis, psoriatic arthritis(PA), atopic dermatitis(AD), and neonatal apnea. In the class of medications that prevent cAMP and/or cGMP degradation, it exhibits smooth muscle relaxation, vasodilatory, and bronchodilatory effects. This activity outline and describes the indications, action, and contraindications for phosphodiesterase inhibitors as a valuable agent in the management of chronic obstructive pulmonary disease(COPD), erectile dysfunction(ED), pulmonary arterial hypertension(PAH), acute decompensated heart failure, psoriasis, psoriatic arthritis(PA), and other disorders when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, monitoring, relevant interactions) pertinent for members of the interprofessional team in the management and care of patients with chronic obstructive pulmonary disease(COPD), erectile dysfunction(ED), pulmonary arterial hypertension(PAH), and related conditions."}
{"id": "article-27139_1", "title": "Phosphodiesterase Inhibitors -- Continuing Education Activity", "content": "Objectives: Describe the mechanism of action of various phosphodiesterase inhibitors. Identify the different classes of phosphodiesterase inhibitors. Outline the proper monitoring for the various classes of phosphodiesterase inhibitors. Summarize the interprofessional team approach for enhancing care coordination and communication to improve phosphodiesterase inhibitors therapy and optimize outcomes. Access free multiple choice questions on this topic.", "contents": "Phosphodiesterase Inhibitors -- Continuing Education Activity. Objectives: Describe the mechanism of action of various phosphodiesterase inhibitors. Identify the different classes of phosphodiesterase inhibitors. Outline the proper monitoring for the various classes of phosphodiesterase inhibitors. Summarize the interprofessional team approach for enhancing care coordination and communication to improve phosphodiesterase inhibitors therapy and optimize outcomes. Access free multiple choice questions on this topic."}
{"id": "article-27139_2", "title": "Phosphodiesterase Inhibitors -- Indications", "content": "Phosphodiesterase inhibitors (PDE inhibitors) are a class of agents acting on specific phosphodiesterase enzymes in target cells and are FDA approved for the management of chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, psoriasis, psoriatic arthritis, and atopic dermatitis. [1] [2] Phosphodiesterase enzymes' essential role serves to separate the phosphate group from the target cell and decrease cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP). The inhibition of these enzymes further prevents the degradation of cAMP or cGMP, exhibiting smooth muscle relaxation, vasodilatory, and bronchodilatory effects. [1]", "contents": "Phosphodiesterase Inhibitors -- Indications. Phosphodiesterase inhibitors (PDE inhibitors) are a class of agents acting on specific phosphodiesterase enzymes in target cells and are FDA approved for the management of chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, psoriasis, psoriatic arthritis, and atopic dermatitis. [1] [2] Phosphodiesterase enzymes' essential role serves to separate the phosphate group from the target cell and decrease cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP). The inhibition of these enzymes further prevents the degradation of cAMP or cGMP, exhibiting smooth muscle relaxation, vasodilatory, and bronchodilatory effects. [1]"}
{"id": "article-27139_3", "title": "Phosphodiesterase Inhibitors -- Indications", "content": "Among the phosphodiesterase inhibitors, sildenafil is the more common agent acting on\u00a0PDE-5 and is FDA-approved in 1998 for erectile dysfunction. [3] Sildenafil use is not limited to the treatment of erectile dysfunction(ED) and obtained FDA approval in 2005 to treat pulmonary arterial hypertension (PAH) in adults. [4] The use of sildenafil in pediatric populations for pulmonary arterial hypertension(PAH)\u00a0has not received approval and is\u00a0considered off-label use. [5] Vardenafil and avanafil are other PDE-5 inhibitors, also approved for erectile dysfunction(ED).\u00a0Tadalafil is a PDE-5 inhibitor approved to treat benign prostatic hyperplasia(BPH) and erectile dysfunction(ED). As both conditions may coincide in the\u00a0later durations of life,\u00a0tadalafil may be used as monotherapy for its therapeutic use to treat both conditions. [6]", "contents": "Phosphodiesterase Inhibitors -- Indications. Among the phosphodiesterase inhibitors, sildenafil is the more common agent acting on\u00a0PDE-5 and is FDA-approved in 1998 for erectile dysfunction. [3] Sildenafil use is not limited to the treatment of erectile dysfunction(ED) and obtained FDA approval in 2005 to treat pulmonary arterial hypertension (PAH) in adults. [4] The use of sildenafil in pediatric populations for pulmonary arterial hypertension(PAH)\u00a0has not received approval and is\u00a0considered off-label use. [5] Vardenafil and avanafil are other PDE-5 inhibitors, also approved for erectile dysfunction(ED).\u00a0Tadalafil is a PDE-5 inhibitor approved to treat benign prostatic hyperplasia(BPH) and erectile dysfunction(ED). As both conditions may coincide in the\u00a0later durations of life,\u00a0tadalafil may be used as monotherapy for its therapeutic use to treat both conditions. [6]"}
{"id": "article-27139_4", "title": "Phosphodiesterase Inhibitors -- Indications", "content": "Cilostazol is a PDE-3 inhibitor that reversibly inhibits platelets from aggregation and is\u00a0indicated to treat intermittent claudication from peripheral arterial disease(PAD). Dipyridamole is also a PDE-3 inhibitor and is used for postoperative prophylaxis for thrombosis, but its action on the PDE-3 enzyme is relatively weak.\u00a0Dipyridamole can also be a diagnostic tool as a pharmacologic nuclear stress test. Dypriadamole increases perfusion to the myocardium, revealing reversible and irreversible ischemic areas in the myocardial muscle. [7]", "contents": "Phosphodiesterase Inhibitors -- Indications. Cilostazol is a PDE-3 inhibitor that reversibly inhibits platelets from aggregation and is\u00a0indicated to treat intermittent claudication from peripheral arterial disease(PAD). Dipyridamole is also a PDE-3 inhibitor and is used for postoperative prophylaxis for thrombosis, but its action on the PDE-3 enzyme is relatively weak.\u00a0Dipyridamole can also be a diagnostic tool as a pharmacologic nuclear stress test. Dypriadamole increases perfusion to the myocardium, revealing reversible and irreversible ischemic areas in the myocardial muscle. [7]"}
{"id": "article-27139_5", "title": "Phosphodiesterase Inhibitors -- Indications", "content": "Milrinone and amrinone also inhibit PDE-3 enzymes, but their actions target heart cells, increasing cAMP in the myocardium, and producing\u00a0a positive inotropic effect.\u00a0Both agents\u00a0may be used short-term for decompensated heart failure as\u00a0therapy for\u00a0greater durations may precipitate ventricular arrhythmias. Roflumilast is a PDE-4 inhibitor that acts on the target cells of lung tissue and is indicated for the treatment of reducing COPD exacerbations. Other PDE-4 inhibitors include\u00a0apremilast and crisaborole; their uses are nonpulmonary, and indications include treating psoriasis, psoriatic arthritis(PA), and atopic dermatitis(AD), respectively, due to their action of decreasing pro-inflammatory chemokines. PDE-4 inhibitors decrease pro-inflammatory mediators and cause bronchodilation by inhibiting the degradation of cAMP. Theophylline is a non-specific\u00a0PDE inhibitor with weak\u00a0action on phosphodiesterase enzymes and has approval for symptomatic relief of chronic obstructive pulmonary disease(COPD). [8]", "contents": "Phosphodiesterase Inhibitors -- Indications. Milrinone and amrinone also inhibit PDE-3 enzymes, but their actions target heart cells, increasing cAMP in the myocardium, and producing\u00a0a positive inotropic effect.\u00a0Both agents\u00a0may be used short-term for decompensated heart failure as\u00a0therapy for\u00a0greater durations may precipitate ventricular arrhythmias. Roflumilast is a PDE-4 inhibitor that acts on the target cells of lung tissue and is indicated for the treatment of reducing COPD exacerbations. Other PDE-4 inhibitors include\u00a0apremilast and crisaborole; their uses are nonpulmonary, and indications include treating psoriasis, psoriatic arthritis(PA), and atopic dermatitis(AD), respectively, due to their action of decreasing pro-inflammatory chemokines. PDE-4 inhibitors decrease pro-inflammatory mediators and cause bronchodilation by inhibiting the degradation of cAMP. Theophylline is a non-specific\u00a0PDE inhibitor with weak\u00a0action on phosphodiesterase enzymes and has approval for symptomatic relief of chronic obstructive pulmonary disease(COPD). [8]"}
{"id": "article-27139_6", "title": "Phosphodiesterase Inhibitors -- Indications", "content": "Pentoxifylline is a xanthine analog and is a non-selective phosphodiesterase inhibitor, FDA approved in 1984 for muscle pain caused by intermittent claudication in chronic peripheral arterial disease. Anagrelide is a PDE-3 inhibitor approved for the treatment of thrombocythemia caused by myeloproliferative disorders.\u00a0Ibudilast is a non-selective PDE inhibitor that has not secured approval by the FDA for its use. Ibudilast action causes dilations of the bronchioles and\u00a0has been used to treat asthma in Japan since 1989. [9] [10] The agent is also said to cross the blood-brain barrier, exert anti-inflammatory actions in the central nervous system, and may be a hopeful agent for inflammatory neurological disorders. [9] [10] Caffeine, one of the most popularly utilized psychoactive compounds used globally, also inhibits phosphodiesterase as one of its three mechanisms of action. It is labeled and generally recognized as safe (GRAS) by the FDA since 1958. [11] [12] Caffeine is a CNS\u00a0stimulant used for fatigue, drowsiness, enhancing memory, cognition, and performance. [12] [11] Caffeine citrate has been used to treat apnea of prematurity in neonates gestation age of twenty-two weeks to less than thirty-three weeks and received approval in 1999 for its use.", "contents": "Phosphodiesterase Inhibitors -- Indications. Pentoxifylline is a xanthine analog and is a non-selective phosphodiesterase inhibitor, FDA approved in 1984 for muscle pain caused by intermittent claudication in chronic peripheral arterial disease. Anagrelide is a PDE-3 inhibitor approved for the treatment of thrombocythemia caused by myeloproliferative disorders.\u00a0Ibudilast is a non-selective PDE inhibitor that has not secured approval by the FDA for its use. Ibudilast action causes dilations of the bronchioles and\u00a0has been used to treat asthma in Japan since 1989. [9] [10] The agent is also said to cross the blood-brain barrier, exert anti-inflammatory actions in the central nervous system, and may be a hopeful agent for inflammatory neurological disorders. [9] [10] Caffeine, one of the most popularly utilized psychoactive compounds used globally, also inhibits phosphodiesterase as one of its three mechanisms of action. It is labeled and generally recognized as safe (GRAS) by the FDA since 1958. [11] [12] Caffeine is a CNS\u00a0stimulant used for fatigue, drowsiness, enhancing memory, cognition, and performance. [12] [11] Caffeine citrate has been used to treat apnea of prematurity in neonates gestation age of twenty-two weeks to less than thirty-three weeks and received approval in 1999 for its use."}
{"id": "article-27139_7", "title": "Phosphodiesterase Inhibitors -- Indications", "content": "Types [13] [14] [15] [1] [2] PDE-3 inhibitors: cilostazol, dipyridamole, milrinone, and amrinone PDE-4 inhibitors: roflumilast, apremilast, crisaborole PDE-5 inhibitors: sildenafil, tadalafil, vardenafil, and avanafil Non-specific PDE inhibitors: theophylline, ibudilast", "contents": "Phosphodiesterase Inhibitors -- Indications. Types [13] [14] [15] [1] [2] PDE-3 inhibitors: cilostazol, dipyridamole, milrinone, and amrinone PDE-4 inhibitors: roflumilast, apremilast, crisaborole PDE-5 inhibitors: sildenafil, tadalafil, vardenafil, and avanafil Non-specific PDE inhibitors: theophylline, ibudilast"}
{"id": "article-27139_8", "title": "Phosphodiesterase Inhibitors -- Indications -- FDA-approved Uses", "content": "Erectile dysfunction(ED): sildenafil, tadalafil, vardenafil, and avanafil Benign prostatic hyperplasia (BPH):\u00a0tadalafil Pulmonary arterial hypertension(PAH):\u00a0 sildenafil,\u00a0tadalafil Psoriatic arthritis(PA): apremilast Psoriasis: apremilast Chronic obstructive pulmonary disease(COPD):\u00a0roflumilast, theophylline Peripheral arterial disease (PAD): cilostazol, pentoxifylline Postoperative thromboembolic prophylaxis: dipyridamole Decompensated cardiac failure: milrinone, amrinone Atopic dermatitis(AD):crisaborole Thrombocythemia: anagrelide Neonatal apnea: caffeine citrate", "contents": "Phosphodiesterase Inhibitors -- Indications -- FDA-approved Uses. Erectile dysfunction(ED): sildenafil, tadalafil, vardenafil, and avanafil Benign prostatic hyperplasia (BPH):\u00a0tadalafil Pulmonary arterial hypertension(PAH):\u00a0 sildenafil,\u00a0tadalafil Psoriatic arthritis(PA): apremilast Psoriasis: apremilast Chronic obstructive pulmonary disease(COPD):\u00a0roflumilast, theophylline Peripheral arterial disease (PAD): cilostazol, pentoxifylline Postoperative thromboembolic prophylaxis: dipyridamole Decompensated cardiac failure: milrinone, amrinone Atopic dermatitis(AD):crisaborole Thrombocythemia: anagrelide Neonatal apnea: caffeine citrate"}
{"id": "article-27139_9", "title": "Phosphodiesterase Inhibitors -- Mechanism of Action", "content": "Cyclic adenosine monophosphate(cAMP) and cyclic guanosine monophosphate (cGMP) are intracellular second messenger molecules degraded and inactivated by the enzyme phosphodiesterases(PDE). [16] [17] [18] Phosphodiesterase inhibitors exert their effects on their targeted phosphodiesterase enzymes(PDE-3, PDE-4, PDE-5), preventing cGMP or cAMP degradation, further increasing\u00a0their levels in smooth muscle cells, causing relaxation and vasodilatory effect in target cells. PDE-3\u00a0inhibitors\u00a0exert\u00a0their effects by increasing cAMP levels in the myocardium, peripheral vasculature, and platelets. This further causes positive inotropic effects by increasing ionized calcium in the myocardium, vasodilation of the peripheral vessels, and preventing platelet aggregation and can be used to treat decompensated cardiac failure and peripheral arterial disease(PAD).", "contents": "Phosphodiesterase Inhibitors -- Mechanism of Action. Cyclic adenosine monophosphate(cAMP) and cyclic guanosine monophosphate (cGMP) are intracellular second messenger molecules degraded and inactivated by the enzyme phosphodiesterases(PDE). [16] [17] [18] Phosphodiesterase inhibitors exert their effects on their targeted phosphodiesterase enzymes(PDE-3, PDE-4, PDE-5), preventing cGMP or cAMP degradation, further increasing\u00a0their levels in smooth muscle cells, causing relaxation and vasodilatory effect in target cells. PDE-3\u00a0inhibitors\u00a0exert\u00a0their effects by increasing cAMP levels in the myocardium, peripheral vasculature, and platelets. This further causes positive inotropic effects by increasing ionized calcium in the myocardium, vasodilation of the peripheral vessels, and preventing platelet aggregation and can be used to treat decompensated cardiac failure and peripheral arterial disease(PAD)."}
{"id": "article-27139_10", "title": "Phosphodiesterase Inhibitors -- Mechanism of Action", "content": "PDE-4 is an enzyme found in cells of the lungs, and PDE-4 inhibitors inhibit the degradation of intracellular cyclic adenosine monophosphate(cAMP) and increase cAMP levels in target cells,\u00a0further causing bronchial muscle relaxation. Along with its effects on the lungs, it also decreases pro-inflammatory mediators. [1] These\u00a0agents are useful in treating COPD, psoriatic arthritis(PA), and atopic dermatitis(AD).\u00a0Crisaborole is a PDE-4 inhibitor indicated for mild to moderate atopic dermatitis, and its mechanism of action its therapeutic\u00a0effect is not fully understood.", "contents": "Phosphodiesterase Inhibitors -- Mechanism of Action. PDE-4 is an enzyme found in cells of the lungs, and PDE-4 inhibitors inhibit the degradation of intracellular cyclic adenosine monophosphate(cAMP) and increase cAMP levels in target cells,\u00a0further causing bronchial muscle relaxation. Along with its effects on the lungs, it also decreases pro-inflammatory mediators. [1] These\u00a0agents are useful in treating COPD, psoriatic arthritis(PA), and atopic dermatitis(AD).\u00a0Crisaborole is a PDE-4 inhibitor indicated for mild to moderate atopic dermatitis, and its mechanism of action its therapeutic\u00a0effect is not fully understood."}
{"id": "article-27139_11", "title": "Phosphodiesterase Inhibitors -- Mechanism of Action", "content": "PDE-5 inhibitors\u00a0carry out their action by preventing the breakdown of cyclic guanosine monophosphate (cGMP), further increasing cGMP levels in target cells. The endothelial cells of the penile smooth muscle corpus cavernosum release nitric oxide(NO), which initiates the enzyme guanylate cyclase, further\u00a0enhancing\u00a0the\u00a0synthesis of cyclic guanosine monophosphate (cGMP). The prevention of\u00a0cGMP breakdown further prolongs an erection and is used therapeutically to treat erectile dysfunction(ED). [14] PDE-5 inhibitors also cause pulmonary vasodilation and may be useful for treating pulmonary arterial hypertension(PAH) as\u00a0PAH may be correlated with the weakened release of nitric oxide in the pulmonary vasculature, resulting in decreased cGMP levels. Nonspecific inhibitors(PDE-3,4,5) exert their action, increasing cAMP levels in the pulmonary vasculature, resulting in bronchial relaxation and further decreasing pro-inflammatory mediators. [19]", "contents": "Phosphodiesterase Inhibitors -- Mechanism of Action. PDE-5 inhibitors\u00a0carry out their action by preventing the breakdown of cyclic guanosine monophosphate (cGMP), further increasing cGMP levels in target cells. The endothelial cells of the penile smooth muscle corpus cavernosum release nitric oxide(NO), which initiates the enzyme guanylate cyclase, further\u00a0enhancing\u00a0the\u00a0synthesis of cyclic guanosine monophosphate (cGMP). The prevention of\u00a0cGMP breakdown further prolongs an erection and is used therapeutically to treat erectile dysfunction(ED). [14] PDE-5 inhibitors also cause pulmonary vasodilation and may be useful for treating pulmonary arterial hypertension(PAH) as\u00a0PAH may be correlated with the weakened release of nitric oxide in the pulmonary vasculature, resulting in decreased cGMP levels. Nonspecific inhibitors(PDE-3,4,5) exert their action, increasing cAMP levels in the pulmonary vasculature, resulting in bronchial relaxation and further decreasing pro-inflammatory mediators. [19]"}
{"id": "article-27139_12", "title": "Phosphodiesterase Inhibitors -- Mechanism of Action", "content": "Theophylline is a nonspecific phosphodiesterase inhibitor used to treat COPD, and the mechanism of action is not\u00a0entirely understood. [19] Although not fully understood, pentoxifylline's mechanism of action is believed to act by the nonselective inhibition of phosphodiesterase enzymes similar to theophylline. This action further enhances blood flow and perfusion in the limbs by increasing erythrocyte flexibility, decreasing blood viscosity, decreasing cell proliferation, and reduced inflammation. This mechanism allows pentoxifylline to be used therapeutically in patients suffering from muscle aches and pain associated with peripheral arterial disease. [20] [21]", "contents": "Phosphodiesterase Inhibitors -- Mechanism of Action. Theophylline is a nonspecific phosphodiesterase inhibitor used to treat COPD, and the mechanism of action is not\u00a0entirely understood. [19] Although not fully understood, pentoxifylline's mechanism of action is believed to act by the nonselective inhibition of phosphodiesterase enzymes similar to theophylline. This action further enhances blood flow and perfusion in the limbs by increasing erythrocyte flexibility, decreasing blood viscosity, decreasing cell proliferation, and reduced inflammation. This mechanism allows pentoxifylline to be used therapeutically in patients suffering from muscle aches and pain associated with peripheral arterial disease. [20] [21]"}
{"id": "article-27139_13", "title": "Phosphodiesterase Inhibitors -- Mechanism of Action", "content": "Anagrelide exerts its effects by inhibiting PDE-3, decreasing the platelet count and platelet aggregation. The full agent's action is still being studied and is said to interrupt the cell cycle post miosis of megakaryocyte development, decreasing\u00a0megakaryocyte's size and ploidy. This drug helps decrease platelet count,\u00a0further preventing thrombotic complications in myeloproliferative disorders such as essential thrombocytopenia, polycythemia vera, and chronic myeloid leukemia. [20] Ibudilast exerts its actions by nonselective phosphodiesterase inhibition of PDE-3, PDE-4, PDE-10, and PDE-11, decreasing nitric oxide production, pro-inflammatory chemokines,\u00a0LTB4, and toll-like receptor 4 (TLR4). [16]", "contents": "Phosphodiesterase Inhibitors -- Mechanism of Action. Anagrelide exerts its effects by inhibiting PDE-3, decreasing the platelet count and platelet aggregation. The full agent's action is still being studied and is said to interrupt the cell cycle post miosis of megakaryocyte development, decreasing\u00a0megakaryocyte's size and ploidy. This drug helps decrease platelet count,\u00a0further preventing thrombotic complications in myeloproliferative disorders such as essential thrombocytopenia, polycythemia vera, and chronic myeloid leukemia. [20] Ibudilast exerts its actions by nonselective phosphodiesterase inhibition of PDE-3, PDE-4, PDE-10, and PDE-11, decreasing nitric oxide production, pro-inflammatory chemokines,\u00a0LTB4, and toll-like receptor 4 (TLR4). [16]"}
{"id": "article-27139_14", "title": "Phosphodiesterase Inhibitors -- Mechanism of Action", "content": "Ibudilast's bronchodilator and anti-inflammatory effects have been used therapeutically in Japan to treat bronchial asthma and post-stroke complications. Caffeine exerts its effects on phosphodiesterase enzymes by nonselective inhibition of PDE1, PDE4, and PDE5, promoting cAMP accumulation. Caffeine also inhibits adenosine and\u00a0gamma-aminobutyric acid (GABA) receptors and enhances intracellular calcium release, improving and enhancing cognition, memory,\u00a0energy, sleep, fatigue, and drowsiness. [22]", "contents": "Phosphodiesterase Inhibitors -- Mechanism of Action. Ibudilast's bronchodilator and anti-inflammatory effects have been used therapeutically in Japan to treat bronchial asthma and post-stroke complications. Caffeine exerts its effects on phosphodiesterase enzymes by nonselective inhibition of PDE1, PDE4, and PDE5, promoting cAMP accumulation. Caffeine also inhibits adenosine and\u00a0gamma-aminobutyric acid (GABA) receptors and enhances intracellular calcium release, improving and enhancing cognition, memory,\u00a0energy, sleep, fatigue, and drowsiness. [22]"}
{"id": "article-27139_15", "title": "Phosphodiesterase Inhibitors -- Administration", "content": "Phosphodiesterase inhibitors (PDE inhibitors) are available\u00a0in\u00a0oral tablets, injection form, and topical ointment. Erectile Dysfunction [13] [14] [23] [24] Sildenafil 25 to 100 mg/day (available in 25 mg, 50 mg, and 100 mg tablets) Vardenafil 5 to 20 mg/day (available in 2.5 mg, 5 mg, 10 mg, 20 mg\u00a0tablets) Tadalafil 5 to 20 mg/day (available in 2.5 mg, 5 mg, 10 mg, and 20 mg\u00a0tablets) Avanafil 50 mg to 200 mg/day (available in 50 mg, 100 mg, and 200 mg tablets) These agents can be\u00a0administered 30 to 60 minutes\u00a0prior to sexual intercourse.", "contents": "Phosphodiesterase Inhibitors -- Administration. Phosphodiesterase inhibitors (PDE inhibitors) are available\u00a0in\u00a0oral tablets, injection form, and topical ointment. Erectile Dysfunction [13] [14] [23] [24] Sildenafil 25 to 100 mg/day (available in 25 mg, 50 mg, and 100 mg tablets) Vardenafil 5 to 20 mg/day (available in 2.5 mg, 5 mg, 10 mg, 20 mg\u00a0tablets) Tadalafil 5 to 20 mg/day (available in 2.5 mg, 5 mg, 10 mg, and 20 mg\u00a0tablets) Avanafil 50 mg to 200 mg/day (available in 50 mg, 100 mg, and 200 mg tablets) These agents can be\u00a0administered 30 to 60 minutes\u00a0prior to sexual intercourse."}
{"id": "article-27139_16", "title": "Phosphodiesterase Inhibitors -- Administration -- Benign Prostatic Hyperplasia (BPH)", "content": "Tadalafil 5 mg/day Tadalafil is available in 2.5 mg, 5 mg, 10 mg, and 20 mg tablets.", "contents": "Phosphodiesterase Inhibitors -- Administration -- Benign Prostatic Hyperplasia (BPH). Tadalafil 5 mg/day Tadalafil is available in 2.5 mg, 5 mg, 10 mg, and 20 mg tablets."}
{"id": "article-27139_17", "title": "Phosphodiesterase Inhibitors -- Administration -- Pulmonary Arterial Hypertension (PAH)", "content": "Sildenafil 20 mg three times per day Tadalafil 40 mg/day Sildenafil is available in 20 mg and 10 mg (12.5ml) vials and can be administered orally or via intravenous injection for pulmonary arterial hypertension.", "contents": "Phosphodiesterase Inhibitors -- Administration -- Pulmonary Arterial Hypertension (PAH). Sildenafil 20 mg three times per day Tadalafil 40 mg/day Sildenafil is available in 20 mg and 10 mg (12.5ml) vials and can be administered orally or via intravenous injection for pulmonary arterial hypertension."}
{"id": "article-27139_18", "title": "Phosphodiesterase Inhibitors -- Administration -- Psoriatic Arthritis (PA)", "content": "Apremilast Day 1: 10 mg/day Day 2: 10 mg twice a day Day 3: 10 mg (morning) and 20 mg (evening) Day 4: 20 mg (morning) and 20 mg (evening) Day 5: 20 mg (morning) and 30 mg (evening) Day 6: 30 mg twice daily Apremilast tablets are available in 10 mg, 20 mg, and 30 mg tablets and are administered orally. Chronic Obstructive Pulmonary Disease (COPD) [15] Theophylline\u00a010\u00a0to 15 mcg/mL serum concentration for acute exacerbation. Roflumilast\u00a0500 mcg/day Theophylline is available in 200 mg, 400 mg, and 800 mg in 5% dextrose for IV injection.Roflumilast\u00a0is available in 500mg tablets for oral administration.", "contents": "Phosphodiesterase Inhibitors -- Administration -- Psoriatic Arthritis (PA). Apremilast Day 1: 10 mg/day Day 2: 10 mg twice a day Day 3: 10 mg (morning) and 20 mg (evening) Day 4: 20 mg (morning) and 20 mg (evening) Day 5: 20 mg (morning) and 30 mg (evening) Day 6: 30 mg twice daily Apremilast tablets are available in 10 mg, 20 mg, and 30 mg tablets and are administered orally. Chronic Obstructive Pulmonary Disease (COPD) [15] Theophylline\u00a010\u00a0to 15 mcg/mL serum concentration for acute exacerbation. Roflumilast\u00a0500 mcg/day Theophylline is available in 200 mg, 400 mg, and 800 mg in 5% dextrose for IV injection.Roflumilast\u00a0is available in 500mg tablets for oral administration."}
{"id": "article-27139_19", "title": "Phosphodiesterase Inhibitors -- Administration -- Peripheral Arterial Disease (PAD)", "content": "Cilostazol\u00a0100 mg\u00a0two times\u00a0a day\u00a0(available in 50 mg and 100 mg tablets and are administered orally) Pentoxifylline 400 mg three times a day\u00a0 (available in 400 mg extended-release tablets and are administered orally)", "contents": "Phosphodiesterase Inhibitors -- Administration -- Peripheral Arterial Disease (PAD). Cilostazol\u00a0100 mg\u00a0two times\u00a0a day\u00a0(available in 50 mg and 100 mg tablets and are administered orally) Pentoxifylline 400 mg three times a day\u00a0 (available in 400 mg extended-release tablets and are administered orally)"}
{"id": "article-27139_20", "title": "Phosphodiesterase Inhibitors -- Administration -- Postoperative Thromboembolic Prophylaxis", "content": "Dipyridamole\u00a075 mg to 100 mg four times\u00a0a day (available in\u00a025 mg, 50 mg, and 75 mg tablets\u00a0and are administered orally) Decompensated Cardiac Failure [25] Milrinone\u00a0100 ng/mL to 300 ng/mL (available in\u00a010 ml, 20 ml, and 50 ml vials for injection) Amrinone\u00a00.5 to 7.0 mcg/mL (available in 5 mg/mL\u00a0for injection)", "contents": "Phosphodiesterase Inhibitors -- Administration -- Postoperative Thromboembolic Prophylaxis. Dipyridamole\u00a075 mg to 100 mg four times\u00a0a day (available in\u00a025 mg, 50 mg, and 75 mg tablets\u00a0and are administered orally) Decompensated Cardiac Failure [25] Milrinone\u00a0100 ng/mL to 300 ng/mL (available in\u00a010 ml, 20 ml, and 50 ml vials for injection) Amrinone\u00a00.5 to 7.0 mcg/mL (available in 5 mg/mL\u00a0for injection)"}
{"id": "article-27139_21", "title": "Phosphodiesterase Inhibitors -- Administration -- Atopic Dermatitis (AD)", "content": "Crisaborole (available as 2% topical ointment) Crisaborole can be used in patients ages two years or older for topical use only. It should be applied to the affected areas two times daily.", "contents": "Phosphodiesterase Inhibitors -- Administration -- Atopic Dermatitis (AD). Crisaborole (available as 2% topical ointment) Crisaborole can be used in patients ages two years or older for topical use only. It should be applied to the affected areas two times daily."}
{"id": "article-27139_22", "title": "Phosphodiesterase Inhibitors -- Administration -- Thrombocythemia", "content": "Anagrelide 0.5 mg 4 times a day or 1mg twice a day. (available in 0.5 mg tablets and are administered orally)", "contents": "Phosphodiesterase Inhibitors -- Administration -- Thrombocythemia. Anagrelide 0.5 mg 4 times a day or 1mg twice a day. (available in 0.5 mg tablets and are administered orally)"}
{"id": "article-27139_23", "title": "Phosphodiesterase Inhibitors -- Administration -- Neonatal Apnea", "content": "Caffeine Citrate 10 mg/ml to 20 mg/ml\u00a0\u00a0(available as a solution for oral and injectable administration)", "contents": "Phosphodiesterase Inhibitors -- Administration -- Neonatal Apnea. Caffeine Citrate 10 mg/ml to 20 mg/ml\u00a0\u00a0(available as a solution for oral and injectable administration)"}
{"id": "article-27139_24", "title": "Phosphodiesterase Inhibitors -- Administration -- Fatigue and Drowsiness", "content": "Caffeine 100 mg to 200 mg (available as tablets or capsules for oral administration). It should not be consumed six hours before bedtime.", "contents": "Phosphodiesterase Inhibitors -- Administration -- Fatigue and Drowsiness. Caffeine 100 mg to 200 mg (available as tablets or capsules for oral administration). It should not be consumed six hours before bedtime."}
{"id": "article-27139_25", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Cilostazol", "content": "Headache Gastrointestinal symptoms: nausea, diarrhea, abnormal stools Tachycardia Palpitations", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Cilostazol. Headache Gastrointestinal symptoms: nausea, diarrhea, abnormal stools Tachycardia Palpitations"}
{"id": "article-27139_26", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Dipyridamole", "content": "Dizziness Gastrointestinal distress Rash Headache Elevated liver enzyme", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Dipyridamole. Dizziness Gastrointestinal distress Rash Headache Elevated liver enzyme"}
{"id": "article-27139_27", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Milrinone", "content": "Ventricular arrhythmias Headache Hypokalemia Tremor", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Milrinone. Ventricular arrhythmias Headache Hypokalemia Tremor"}
{"id": "article-27139_28", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Amrinone", "content": "Thrombocytopenia Gastrointestinal symptoms: nausea, vomiting, abdominal pain Arrhythmia Hepatotoxicity Hypersensitivity", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Amrinone. Thrombocytopenia Gastrointestinal symptoms: nausea, vomiting, abdominal pain Arrhythmia Hepatotoxicity Hypersensitivity"}
{"id": "article-27139_29", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Roflumilast", "content": "Gastrointestinal symptoms: nausea, vomiting, diarrhea Weight loss Decreased appetite Headache Insomnia Dizziness Anxiety Worsening depression", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Roflumilast. Gastrointestinal symptoms: nausea, vomiting, diarrhea Weight loss Decreased appetite Headache Insomnia Dizziness Anxiety Worsening depression"}
{"id": "article-27139_30", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Apremilast", "content": "Gastrointestinal symptoms: nausea, vomiting, diarrhea Headache Worsening depression Suicidal thoughts Weight loss Upper respiratory infections", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Apremilast. Gastrointestinal symptoms: nausea, vomiting, diarrhea Headache Worsening depression Suicidal thoughts Weight loss Upper respiratory infections"}
{"id": "article-27139_31", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Crisaborole", "content": "Burning on the site of application Hypersensitivity: pruritis, swelling, erythema", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Crisaborole. Burning on the site of application Hypersensitivity: pruritis, swelling, erythema"}
{"id": "article-27139_32", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Sildenafil", "content": "Headache Flushing Visual disturbance Gastrointestinal symptoms: dyspepsia, nausea Nasal congestion Priapism Hearing loss Back pain Decreased in blood pressure Rash Dizziness Hepatotoxicity", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Sildenafil. Headache Flushing Visual disturbance Gastrointestinal symptoms: dyspepsia, nausea Nasal congestion Priapism Hearing loss Back pain Decreased in blood pressure Rash Dizziness Hepatotoxicity"}
{"id": "article-27139_33", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Tadalafil", "content": "Headache (most common) Decreased in blood pressure Nasopharyngitis Myalgia Back pain Priapism Hearing loss Visual disturbance", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Tadalafil. Headache (most common) Decreased in blood pressure Nasopharyngitis Myalgia Back pain Priapism Hearing loss Visual disturbance"}
{"id": "article-27139_34", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Vardenafil", "content": "Headache Flushing Flu-like symptoms Sinusitis Gastrointestinal symptoms: dyspepsia, nausea Priapism Hearing loss Increased creatinine kinase levels QT prolongation", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Vardenafil. Headache Flushing Flu-like symptoms Sinusitis Gastrointestinal symptoms: dyspepsia, nausea Priapism Hearing loss Increased creatinine kinase levels QT prolongation"}
{"id": "article-27139_35", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Avanafil", "content": "Headache Flushing Back pain Nasal congestion", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Avanafil. Headache Flushing Back pain Nasal congestion"}
{"id": "article-27139_36", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Theophylline", "content": "Hypotension Tachycardia Gastrointestinal symptoms: nausea, vomiting Seizures Arrhythmias", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Theophylline. Hypotension Tachycardia Gastrointestinal symptoms: nausea, vomiting Seizures Arrhythmias"}
{"id": "article-27139_37", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Pentoxifylline", "content": "Gastrointestinal symptoms: dyspepsia, nausea, vomiting Dizziness Chest pain Arrhythmia Headache", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Pentoxifylline. Gastrointestinal symptoms: dyspepsia, nausea, vomiting Dizziness Chest pain Arrhythmia Headache"}
{"id": "article-27139_38", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Anagrelide", "content": "Headache Palpitations Decreased blood pressure Diahrrea Asthenia Edema Gastrointestinal symptoms: dyspepsia, nausea, vomiting", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Anagrelide. Headache Palpitations Decreased blood pressure Diahrrea Asthenia Edema Gastrointestinal symptoms: dyspepsia, nausea, vomiting"}
{"id": "article-27139_39", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Ibudilast", "content": "Hyperhidrosis Headache Gastrointestinal symptoms: nausea, vomiting, diarrhea", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Ibudilast. Hyperhidrosis Headache Gastrointestinal symptoms: nausea, vomiting, diarrhea"}
{"id": "article-27139_40", "title": "Phosphodiesterase Inhibitors -- Adverse Effects -- Caffeine", "content": "Tachycardia Palpitations Irritability Restlessness Decreased sleep Tremor Gastrointestinal symptoms: nausea, vomiting, diarrhea", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects -- Caffeine. Tachycardia Palpitations Irritability Restlessness Decreased sleep Tremor Gastrointestinal symptoms: nausea, vomiting, diarrhea"}
{"id": "article-27139_41", "title": "Phosphodiesterase Inhibitors -- Adverse Effects", "content": "Sildenafil, vardenafil, and tadalafil have been\u00a0associated\u00a0with hearing loss. [26] Often the hearing loss is unilateral and may\u00a0occur during the initial 24 hours after\u00a0administration of\u00a0the agent and is temporary in almost one-third of patients. [27] Patients should seek immediate medical\u00a0attention\u00a0if hearing loss does pursue. Although sildenafil is a PDE-5 inhibitor, it mildly has an inhibitory effect on a phosphodiesterase-6 enzyme found in the retinal rod and cone receptors. This may result in a \"blue-tinted\" visual disturbance in some subjects taking higher doses. [28] Patients also may experience increased sensitivity to the brightness of lights.", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects. Sildenafil, vardenafil, and tadalafil have been\u00a0associated\u00a0with hearing loss. [26] Often the hearing loss is unilateral and may\u00a0occur during the initial 24 hours after\u00a0administration of\u00a0the agent and is temporary in almost one-third of patients. [27] Patients should seek immediate medical\u00a0attention\u00a0if hearing loss does pursue. Although sildenafil is a PDE-5 inhibitor, it mildly has an inhibitory effect on a phosphodiesterase-6 enzyme found in the retinal rod and cone receptors. This may result in a \"blue-tinted\" visual disturbance in some subjects taking higher doses. [28] Patients also may experience increased sensitivity to the brightness of lights."}
{"id": "article-27139_42", "title": "Phosphodiesterase Inhibitors -- Adverse Effects", "content": "These visual disruptions due to the electrical responses to light are temporary and reversible. [29] Priapism is a reported adverse effect of phosphodiesterase-5 inhibitors. Patients who have erections lasting more than four hours should seek medical attention as permanent damage may result. Apremilast has an increased risk of depression. Patients\u00a0who have an underlying history of depression should be evaluated thoroughly prior to the initiation of apremilast.\u00a0Roflumilast may also worsen underlying depression or increased suicidal thoughts; a thorough\u00a0assessment should be conducted before therapy.", "contents": "Phosphodiesterase Inhibitors -- Adverse Effects. These visual disruptions due to the electrical responses to light are temporary and reversible. [29] Priapism is a reported adverse effect of phosphodiesterase-5 inhibitors. Patients who have erections lasting more than four hours should seek medical attention as permanent damage may result. Apremilast has an increased risk of depression. Patients\u00a0who have an underlying history of depression should be evaluated thoroughly prior to the initiation of apremilast.\u00a0Roflumilast may also worsen underlying depression or increased suicidal thoughts; a thorough\u00a0assessment should be conducted before therapy."}
{"id": "article-27139_43", "title": "Phosphodiesterase Inhibitors -- Contraindications", "content": "Hypersensitivity is an absolute contraindication to all\u00a0phosphodiesterase inhibitors. Nitrites are contraindicated to use alongside PDE-5 inhibitors: sildenafil, tadalafil, vardenafil, and avanafil, as they may\u00a0result in severe hypotension. [30] Relative contraindication such as pre-existing cardiovascular disease, resting hypotension, and anti-hypertensive use require evaluation before\u00a0phosphodiesterase inhibitor use.", "contents": "Phosphodiesterase Inhibitors -- Contraindications. Hypersensitivity is an absolute contraindication to all\u00a0phosphodiesterase inhibitors. Nitrites are contraindicated to use alongside PDE-5 inhibitors: sildenafil, tadalafil, vardenafil, and avanafil, as they may\u00a0result in severe hypotension. [30] Relative contraindication such as pre-existing cardiovascular disease, resting hypotension, and anti-hypertensive use require evaluation before\u00a0phosphodiesterase inhibitor use."}
{"id": "article-27139_44", "title": "Phosphodiesterase Inhibitors -- Contraindications", "content": "Heart failure of any sort is a contraindication to\u00a0cilostazol use. Patients taking medications that may cause QT prolongation or have congenital QT syndrome should avoid taking\u00a0vardenafil. Patients with hemostatic or bleeding disorders are contraindicated to\u00a0cilostazol use as its mechanism of action inhibits platelet aggregations and\u00a0may worsen the underlying conditions. Milrinone and amrinone are contraindicated in patients with pre-existing valvular disease of the aortic or pulmonic valve as they may cause outflow obstruction. Pentoxifylline is contraindicated in patients with a recent history of cerebral hemorrhage or retinal hemorrhage.", "contents": "Phosphodiesterase Inhibitors -- Contraindications. Heart failure of any sort is a contraindication to\u00a0cilostazol use. Patients taking medications that may cause QT prolongation or have congenital QT syndrome should avoid taking\u00a0vardenafil. Patients with hemostatic or bleeding disorders are contraindicated to\u00a0cilostazol use as its mechanism of action inhibits platelet aggregations and\u00a0may worsen the underlying conditions. Milrinone and amrinone are contraindicated in patients with pre-existing valvular disease of the aortic or pulmonic valve as they may cause outflow obstruction. Pentoxifylline is contraindicated in patients with a recent history of cerebral hemorrhage or retinal hemorrhage."}
{"id": "article-27139_45", "title": "Phosphodiesterase Inhibitors -- Contraindications -- Black Box Warning", "content": "Cilostazol: Heart failure is an absolute contraindication to\u00a0cilostazol use. Milrinone: Should not be used for greater than 48 hours for heart failure as it may cause ventricular arrhythmias and result in sudden death.", "contents": "Phosphodiesterase Inhibitors -- Contraindications -- Black Box Warning. Cilostazol: Heart failure is an absolute contraindication to\u00a0cilostazol use. Milrinone: Should not be used for greater than 48 hours for heart failure as it may cause ventricular arrhythmias and result in sudden death."}
{"id": "article-27139_46", "title": "Phosphodiesterase Inhibitors -- Monitoring", "content": "Medications that cause vasodilatory effects, such as antihypertensives, alpha-blockers, and amlodipine, should be avoided with concomitant use with phosphodiesterase-5 inhibitors. If used in sequence, patients should have routine monitoring, and therapy should be started on the lowest possible dosage as it\u00a0may result in\u00a0profound\u00a0hypotension, lightheadedness, and dizziness. Patients with renal insufficiency and\u00a0hepatic impairment\u00a0can result in higher serum concentrations of medication; dose adjustment may be necessary. Fluid and electrolytes require monitoring routinely with\u00a0milrinone use as it may precipitate hypokalemia and induce arrhythmias. Precautions are necessary for patients with underlying ophthalmopathy taking sildenafil, vardenafil, tadalafil, and avanafil as unexpected vision loss may occur unilaterally or bilaterally, which may be an indication of non-arteritic anterior ischemic optic neuropathy (NAION). [31]", "contents": "Phosphodiesterase Inhibitors -- Monitoring. Medications that cause vasodilatory effects, such as antihypertensives, alpha-blockers, and amlodipine, should be avoided with concomitant use with phosphodiesterase-5 inhibitors. If used in sequence, patients should have routine monitoring, and therapy should be started on the lowest possible dosage as it\u00a0may result in\u00a0profound\u00a0hypotension, lightheadedness, and dizziness. Patients with renal insufficiency and\u00a0hepatic impairment\u00a0can result in higher serum concentrations of medication; dose adjustment may be necessary. Fluid and electrolytes require monitoring routinely with\u00a0milrinone use as it may precipitate hypokalemia and induce arrhythmias. Precautions are necessary for patients with underlying ophthalmopathy taking sildenafil, vardenafil, tadalafil, and avanafil as unexpected vision loss may occur unilaterally or bilaterally, which may be an indication of non-arteritic anterior ischemic optic neuropathy (NAION). [31]"}
{"id": "article-27139_47", "title": "Phosphodiesterase Inhibitors -- Monitoring", "content": "Phosphodiesterase-5 inhibitors are substantially and quickly metabolized by the CYP3A4 enzyme found in the liver. [3] CYP3A4 inhibitors such as ritonavir, ketoconazole, verapamil, itraconazole erythromycin, and grapefruit juice can increase serum concentrations of PDE-inhibitors and require dosing adjustments. Patients taking\u00a0cilostazol to manage peripheral arterial disease(PAD) should\u00a0routinely monitor platelet, and WBC counts as thrombocytopenia or leukopenia can develop.\u00a0Dipyridamole may cause an elevation in liver enzymes and should be monitored routinely and used with precaution in patients with pre-existing liver insufficiency. Amirinone use may cause thrombocytopenia and is hepatotoxic; platelet count and liver enzymes should be monitored routinely. Thrombocytopenia from amrinone may be dose-dependent and is said to be non-immune mediated. [32]", "contents": "Phosphodiesterase Inhibitors -- Monitoring. Phosphodiesterase-5 inhibitors are substantially and quickly metabolized by the CYP3A4 enzyme found in the liver. [3] CYP3A4 inhibitors such as ritonavir, ketoconazole, verapamil, itraconazole erythromycin, and grapefruit juice can increase serum concentrations of PDE-inhibitors and require dosing adjustments. Patients taking\u00a0cilostazol to manage peripheral arterial disease(PAD) should\u00a0routinely monitor platelet, and WBC counts as thrombocytopenia or leukopenia can develop.\u00a0Dipyridamole may cause an elevation in liver enzymes and should be monitored routinely and used with precaution in patients with pre-existing liver insufficiency. Amirinone use may cause thrombocytopenia and is hepatotoxic; platelet count and liver enzymes should be monitored routinely. Thrombocytopenia from amrinone may be dose-dependent and is said to be non-immune mediated. [32]"}
{"id": "article-27139_48", "title": "Phosphodiesterase Inhibitors -- Monitoring", "content": "Patients receiving treatment milrinone should be monitored via EKG as it can precipitate ventricular arrhythmias. Electrolytes should also be monitored with milrinone use as it can decrease serum potassium. Patients being treated with roflumilast and\u00a0apremilast should be followed for alterations in mood, such as worsening depression or suicidal thoughts, as it may precipitate underlying or undiagnosed mood disorders.\u00a0Anagrelide serum concentration can increase eightfold in\u00a0hepatic impairment. Liver function tests should be conducted before therapy, and platelet count requires routine monitoring for patients taking this medication. Pregnancy Category B: apremilast, tadalafil, vardenafil,\u00a0dipyridamole Pregnancy Category C: sildenafil, theophylline, roflumilast,\u00a0avanafil,\u00a0cilostazol, milrinone, anagrelide", "contents": "Phosphodiesterase Inhibitors -- Monitoring. Patients receiving treatment milrinone should be monitored via EKG as it can precipitate ventricular arrhythmias. Electrolytes should also be monitored with milrinone use as it can decrease serum potassium. Patients being treated with roflumilast and\u00a0apremilast should be followed for alterations in mood, such as worsening depression or suicidal thoughts, as it may precipitate underlying or undiagnosed mood disorders.\u00a0Anagrelide serum concentration can increase eightfold in\u00a0hepatic impairment. Liver function tests should be conducted before therapy, and platelet count requires routine monitoring for patients taking this medication. Pregnancy Category B: apremilast, tadalafil, vardenafil,\u00a0dipyridamole Pregnancy Category C: sildenafil, theophylline, roflumilast,\u00a0avanafil,\u00a0cilostazol, milrinone, anagrelide"}
{"id": "article-27139_49", "title": "Phosphodiesterase Inhibitors -- Toxicity", "content": "PDE-4 inhibitor theophylline serum concentrations of more than 20 mcg/mL are in a toxic range. [33] Theophylline-induced seizures and arrhythmias prompt treatment immediately as it may result in mortality from hemodynamic compromise at serum concentrations of 30 mcg/mL or greater. Therapy with anticonvulsants such as benzodiazepine and antiarrhythmic treatment should start immediately. PDE-5 and PDE-3 inhibitors undergo hepatic metabolism, and inhibitors of CYP3A4 or CYP2C19 can increase the serum drug concentrations of therapy. Dose modifications are required before the initiation of treatment to avoid adverse effects.", "contents": "Phosphodiesterase Inhibitors -- Toxicity. PDE-4 inhibitor theophylline serum concentrations of more than 20 mcg/mL are in a toxic range. [33] Theophylline-induced seizures and arrhythmias prompt treatment immediately as it may result in mortality from hemodynamic compromise at serum concentrations of 30 mcg/mL or greater. Therapy with anticonvulsants such as benzodiazepine and antiarrhythmic treatment should start immediately. PDE-5 and PDE-3 inhibitors undergo hepatic metabolism, and inhibitors of CYP3A4 or CYP2C19 can increase the serum drug concentrations of therapy. Dose modifications are required before the initiation of treatment to avoid adverse effects."}
{"id": "article-27139_50", "title": "Phosphodiesterase Inhibitors -- Toxicity", "content": "Although uncommon with sildenafil use, Hepatoxicity has been reported,\u00a0but studies\u00a0of the correlation are limited. [3] Anagrelide should not be administered in patients with pre-existing liver disease as it can result in large increases in drug concentration. Drug toxicity may ensue with a dosage of 10 mg per day or greater or 2.5 mg in a single dose of anagrelide.\u00a0Caffeine toxicities can pursue at 50 mg/L to 350 mg/L, causing arrhythmias, seizures, and mortality. [34] Caffeine toxicity-induced seizures can be treated with benzodiazepines, and dysrhythmias\u00a0have shown successful\u00a0recovery with the treatment\u00a0of beta-blockers such as metoprolol or esmolol. [35] [36]", "contents": "Phosphodiesterase Inhibitors -- Toxicity. Although uncommon with sildenafil use, Hepatoxicity has been reported,\u00a0but studies\u00a0of the correlation are limited. [3] Anagrelide should not be administered in patients with pre-existing liver disease as it can result in large increases in drug concentration. Drug toxicity may ensue with a dosage of 10 mg per day or greater or 2.5 mg in a single dose of anagrelide.\u00a0Caffeine toxicities can pursue at 50 mg/L to 350 mg/L, causing arrhythmias, seizures, and mortality. [34] Caffeine toxicity-induced seizures can be treated with benzodiazepines, and dysrhythmias\u00a0have shown successful\u00a0recovery with the treatment\u00a0of beta-blockers such as metoprolol or esmolol. [35] [36]"}
{"id": "article-27139_51", "title": "Phosphodiesterase Inhibitors -- Enhancing Healthcare Team Outcomes", "content": "Phosphodiesterase inhibitors (PDE inhibitors) are a class of agents acting on phosphodiesterase enzymes. They are FDA approved to manage chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, acute decompensated heart failure, psoriasis, psoriatic arthritis, atopic dermatitis, and neonatal apnea. The management of patients administered PDE inhibitors requires decisive care and decision-making from an interprofessional team of healthcare professionals, as the management of each condition can lead to a better quality of life for patients. These healthcare professionals include a primary care provider, a specialist (cardiologist, pulmonologist, urologist, or rheumatologist), depending on the management of the disease, a nurse, and a pharmacist. The primary care provider and specialist should be familiar with PDE inhibitors, their indications and use, adverse effects, and contraindications. In addition, patients should be fully educated on the side effects of therapy, such as headaches and decreased blood pressure that may cause dizziness and lightheadedness.", "contents": "Phosphodiesterase Inhibitors -- Enhancing Healthcare Team Outcomes. Phosphodiesterase inhibitors (PDE inhibitors) are a class of agents acting on phosphodiesterase enzymes. They are FDA approved to manage chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, acute decompensated heart failure, psoriasis, psoriatic arthritis, atopic dermatitis, and neonatal apnea. The management of patients administered PDE inhibitors requires decisive care and decision-making from an interprofessional team of healthcare professionals, as the management of each condition can lead to a better quality of life for patients. These healthcare professionals include a primary care provider, a specialist (cardiologist, pulmonologist, urologist, or rheumatologist), depending on the management of the disease, a nurse, and a pharmacist. The primary care provider and specialist should be familiar with PDE inhibitors, their indications and use, adverse effects, and contraindications. In addition, patients should be fully educated on the side effects of therapy, such as headaches and decreased blood pressure that may cause dizziness and lightheadedness."}
{"id": "article-27139_52", "title": "Phosphodiesterase Inhibitors -- Enhancing Healthcare Team Outcomes", "content": "The patient should also be advised to seek medical attention immediately if more concerning effects such as visual disturbances, hearing loss, and priapism for long periods occur using PDE-5 inhibitors (sildenafil, tadalafil, vardenafil, and avanafil). The elderly population prescribed therapy for erectile dysfunction should be thoroughly evaluated in case dosing modifications may be needed for renal and hepatic impairment in this patient population. The clinician should be aware of any other medications the patient may be taking short-term or long-term. Phosphodiesterase inhibitors can cross-react with other agents as they are metabolized by the cytochrome p450 system in the liver resulting in subtherapeutic or toxic serum concentrations.", "contents": "Phosphodiesterase Inhibitors -- Enhancing Healthcare Team Outcomes. The patient should also be advised to seek medical attention immediately if more concerning effects such as visual disturbances, hearing loss, and priapism for long periods occur using PDE-5 inhibitors (sildenafil, tadalafil, vardenafil, and avanafil). The elderly population prescribed therapy for erectile dysfunction should be thoroughly evaluated in case dosing modifications may be needed for renal and hepatic impairment in this patient population. The clinician should be aware of any other medications the patient may be taking short-term or long-term. Phosphodiesterase inhibitors can cross-react with other agents as they are metabolized by the cytochrome p450 system in the liver resulting in subtherapeutic or toxic serum concentrations."}
{"id": "article-27139_53", "title": "Phosphodiesterase Inhibitors -- Enhancing Healthcare Team Outcomes", "content": "Cardiac risk factors should be carefully assessed before treatment as this class of medications may cause a decrease in blood pressure and precipitate or further worsen an underlying cardiac disease. Patients taking antihypertensives should be advised about their concurrent use with phosphodiesterase inhibitors as it can cause symptomatic life-threatening hypotension. PDE-4 inhibitors may worsen or precipitate psychiatric symptoms such as suicidal thoughts and depression in susceptible individuals. The use of this medication class can be discussed with a psychiatrist before administration in select individuals.", "contents": "Phosphodiesterase Inhibitors -- Enhancing Healthcare Team Outcomes. Cardiac risk factors should be carefully assessed before treatment as this class of medications may cause a decrease in blood pressure and precipitate or further worsen an underlying cardiac disease. Patients taking antihypertensives should be advised about their concurrent use with phosphodiesterase inhibitors as it can cause symptomatic life-threatening hypotension. PDE-4 inhibitors may worsen or precipitate psychiatric symptoms such as suicidal thoughts and depression in susceptible individuals. The use of this medication class can be discussed with a psychiatrist before administration in select individuals."}
{"id": "article-27139_54", "title": "Phosphodiesterase Inhibitors -- Enhancing Healthcare Team Outcomes", "content": "Nonselective phosphodiesterase inhibitors such as theophylline and caffeine should be used cautiously as toxicity can result in seizures, arrhythmias, and mortality. If seizures or arrhythmias occur, patients should be treated promptly with benzodiazepines and beta-blockers as indicated and as needed until the patient is stabilized. The primary care clinician should periodically monitor patients as some phosphodiesterase inhibitors may cause elevations in liver enzymes, thrombocytopenia, and electrolyte disturbances. Joint decision-making and interprofessional interaction are essential components to decrease adverse effects and enhance patient-centered care to achieve the desired outcome.", "contents": "Phosphodiesterase Inhibitors -- Enhancing Healthcare Team Outcomes. Nonselective phosphodiesterase inhibitors such as theophylline and caffeine should be used cautiously as toxicity can result in seizures, arrhythmias, and mortality. If seizures or arrhythmias occur, patients should be treated promptly with benzodiazepines and beta-blockers as indicated and as needed until the patient is stabilized. The primary care clinician should periodically monitor patients as some phosphodiesterase inhibitors may cause elevations in liver enzymes, thrombocytopenia, and electrolyte disturbances. Joint decision-making and interprofessional interaction are essential components to decrease adverse effects and enhance patient-centered care to achieve the desired outcome."}
{"id": "article-27139_55", "title": "Phosphodiesterase Inhibitors -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Phosphodiesterase Inhibitors -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}